Prognostic Significance of Key Molecular Markers in Thyroid Cancer: A Systematic Literature Review and Meta-Analysis
Cancers · 10.03.2025 · 17 (6) · 939
DOI: 10.3390/cancers17060939 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 10.03.2025. Verfasst von Linh T T Nguyen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Kolling Institute, Northern Sydney Local Health District and Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Thyroid cancer (TC) involves diverse genetic alterations, with their prognostic significance often debated.
Objectives
This study evaluates the impact of BRAF, TERT promoter, TP53, and PI3K pathway mutations detected via Next-Generation Sequencing (NGS) on overall survival (OS) and disease-free survival (DFS) in follicular-derived TC patients.
Methods
A comprehensive search was conducted in MEDLINE, Scopus, and EMBASE databases from 2013 to 2023 for studies using NGS on TC patients. Hazard ratios (HR) and 95% confidence intervals (CI) for OS and DFS were extracted from original studies or estimated from Kaplan–Meier curves (KMC). A random-effects model, weighted by inverse variance, was used to calculate pooled HRs. Publication bias was assessed using Egger’s regression test and visual funnel plot analysis.
Results
Of the 3921 initial studies, nine studies involving 1075 patients were included in the meta-analysis. BRAF mutations showed no significant effect on OS (HR = 1.11, 95% CI: 0.66–1.88) or DFS (HR = 1.23, 95% CI: 0.66–2.29). In contrast, TERT promoter mutations were strongly associated with worse OS (HR = 1.90, 95% CI: 1.17–3.09) and DFS (HR = 2.76, 95% CI: 1.86–4.10). TP53 and PI3K pathway mutations were linked to shorter OS (HR = 2.87, 95% CI: 1.44–5.86 and HR = 2.17, 95% CI: 1.05–4.15, respectively), though their impact on DFS remains unclear due to limited data.
Conclusions
These findings highlight TERT promoter mutations as strong prognostic markers for both OS and DFS, while TP53 and PI3K mutations indicate higher mortality risk.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kolling Institute, Northern Sydney Local Health District and Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2050, Australia.
- Department of Endocrinology, The 108 Military Central Hospital, Hanoi 100000, Vietnam.
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Darlinghurst, NSW 2010, Australia.
- Specialty of Surgery, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia.
- School of Population Health, University of New South Wales, Sydney, NSW 2033, Australia.
- School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia.
ORCID-Profile: Nazim Bhimani, Minh C Duong, Huy G Nguyen, Martyn Bullock, Matti L Gild, Anthony Glover
Zitieren
APA
Nguyen, L. T. T., Thompson, E. K., Bhimani, N., Duong, M. C., Nguyen, H. G., Bullock, M., Gild, M. L., & Glover, A. (2025). Prognostic Significance of Key Molecular Markers in Thyroid Cancer: A Systematic Literature Review and Meta-Analysis. Cancers, 17(6), 939. https://doi.org/10.3390/cancers17060939
Vancouver
Nguyen LTT, Thompson EK, Bhimani N, Duong MC, Nguyen HG, Bullock M, et al. Prognostic Significance of Key Molecular Markers in Thyroid Cancer: A Systematic Literature Review and Meta-Analysis. Cancers. 2025;17(6):939. doi:10.3390/cancers17060939
BibTeX
@article{Nguyen2025,
author = {Nguyen, Linh T T and Thompson, Emma K and Bhimani, Nazim and Duong, Minh C and Nguyen, Huy G and Bullock, Martyn and Gild, Matti L and Glover, Anthony},
title = {Prognostic Significance of Key Molecular Markers in Thyroid Cancer: A Systematic Literature Review and Meta-Analysis},
journal = {Cancers},
year = {2025},
volume = {17},
number = {6},
pages = {939},
doi = {10.3390/cancers17060939}
}
EUVIMED